ABVX - ABIVAX Debt to Book Capitalization Ratio
ABIVAX (ABVX) is betting on large-scale success in immunology, where FDA approval for ulcerative colitis drugs promises colossal profits. The price action on GURU.Markets, which stands at 0.00, confirms market expectations. The company is optimizing costs by outsourcing testing and drug production to third-party contractors. Currently, the business is funded by venture investments, gradually utilizing existing capital until it reaches break-even.
%20Debt%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_ABVX_-_ABIVAX_-_Debt-to-Net-Assets-Ratio "Abivax S.A. - ABVX Debt to Book Capitalization Ratio (period 02/21/2024 - 10/28/2026) | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for ABIVAX (ABVX)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Summary company analytics:Abivax SA (ABVX)
ABIVAX's extensive partnerships with research centers and pharma behemoths require precise capital management to fund drug development. This indicator compares total liabilities to the book value of equity, allowing investors to assess debt load and financial stability through real-time fluctuations in the debt-to-book capitalization ratio.
Who ABIVAX competes with
Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ADMA Biologics, Inc. (ADMA)|PTGX: Debt to Net Assets Ratio|IMVT (Immunovant Corp) - Debt to Book Capitalization Ratio|Kiniksa Corp (KNSA) - Debt to Book Value|GRFS (Grifols, S.A.) - Debts to Book Capitalization|Debts to Book Capitalization adaptivebiotech.com (ADPT)|Celldex Therapeutics, Inc. (CLDX) - Debt to Book Value|Debt to Net Assets Ratio Aurinia Pharmaceuticals Inc (AUPH)|Debts to Book Capitalization BCRX|Vera Corp - Debts to Net Assets|DNTH: Debt to Book Capitalization Ratio|PHVS: Debt to Book Value|ABCL (AbCellera Corp) - Debt to Book Capitalization Ratio|Debt to Book Value Tourmaline Bio Inc|PGEN (Intrexon) - Debt to Book Value|Debts to Book Capitalization PHAR|Debt to Book Capitalization Ratio Nektar Therapeutics NKTR|Debt to Book Value Ratio upstreambio.com (UPB)|ZBIO: Debts to Book Capitalization|Debts to Book Value Immunome Inc IMNM|Gossamer Corp - Debts to Book Capitalization|KALV - Debts to Book Capitalization|Septerna Inc (SEPN) - Debts to Book Capitalization|pieris.com (PVLA) - Debt to Book Capitalization Ratio|SVRA: Debts to Book Capitalization|Debts to Net Assets Rigel Pharma (RIGL)|Debt to Book Value AnaptysBio Corp (ANAB)|Debt to Book Capitalization Ratio Astria Corp (ATXS)|Debts to Book Capitalization ENGN (enGene Holdings Inc.)|RAPT - Debts to Book Capitalization|Aerovate (JBIO) - Debt to Book Value|ACRS - Debt to Book Value Ratio|KYTX: Debts to Book Capitalization|Tiziana Life Sciences, Ltd. (TLSA) - Debts to Book Capitalization|Debts to Book Capitalization Cabaletta Bio, Inc.|Debt to Book Capitalization Ratio ventyxbio.com (VTYX)|Debt to Book Value Theratechnologies (THTX)|Debt to Book Capitalization Ratio Avalo Therapeutics, Inc. AVTX|ELDN - Debt to Book Value|Agenus, Inc - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Climb Bio Inc|ZURA - Debts to Book Capitalization Ratio|Debts to Book Capitalization aTyr Pharma ATYR|Adagene Inc. (ADAG) - Debt to Net Assets Ratio|IMA (ImageneBio) - Debts to Book Capitalization|Debts to Book Capitalization STTK|Equillium, Inc. (EQ) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio CNTB (connectbiopharm.com)|Immunic - Debt to Book Capitalization Ratio|Debt to Book Value Atara Biotherapeutics, Inc. ATRA|InflaRx GmbH - Debts to Book Capitalization|X4 Pharmaceuticals, Inc (XFOR) - Debts to Book Capitalization|Debt to Book Value adicetbio.com ACET|Celularity (CELU) - Debt to Net Assets Ratio|INMB: Debts to Book Capitalization|Debts to Net Assets BRNS|Debt to Book Capitalization Ratio KZR (Kezar Life Sciences, Inc)|Debt to Book Value SABS (SAB Biotherapeutics Inc)|Akari Therapeutics - Debt to Book Capitalization Ratio|ENLV - Debt to Book Value|Q32 Bio Corp - Debt to Book Value|GOVX: Debts to Book Capitalization|Debt to Book Capitalization Ratio Edesa|iBio Corporation (IBIO) - Debt to Book Value Ratio|Debts to Book Capitalization CARM (Carisma Therapeutics Inc)|Debts to Book Value xtlbio.com|Debts to Book Capitalization BOLT|Debts to Book Capitalization hcwbiologics.com (HCWB)|Debts to Book Capitalization Aptevo Therapeutics Inc. APVO|Debt to Book Capitalization Ratio AIM ImmunoTech, Inc. AIM|Debts to Book Capitalization ADTX (Aditxt Corp)|gribio.com (GRI) - Debts to Net Assets|XORTX Therapeutics (XRTX) - Debt to Book Value|Vyome Holdings Inc. (HIND) - Debt to Book Capitalization Ratio|REVB (Revelation Bio) - Debts to Book Capitalization|Debts to Book Capitalization Indaptus Corp (INDP)|Debt to Book Value Scinai Immunotherapeutics SCNI|Debt to Book Value Ratio calcimedica.com (CALI)|Debts to Book Capitalization AFMD (Affimed N.V.)|Debts to Book Capitalization Allakos Inc ALLK|HOOK - Debts to Book Capitalization|IGM Biosciences, Inc. (IGMS) - Debt to Book Capitalization Ratio|iTeos Therapeutics (ITOS) - Debt to Book Value|Debt to Book Capitalization Ratio oceanbiomedical.com|Debt to Book Value TC BioPharm (TCBP)|Debt to Book Value Ratio THRD